AI Article Synopsis
- No large-scale studies exist that examine the demographic and clinical factors influencing rhabdomyolysis patients, especially concerning those with and without acute kidney injury (AKI).
- The research utilized data from the National Inpatient Sample (2016-2018) to analyze hospitalization data, employing various statistical tests to examine the impact of AKI on these patients.
- Findings revealed that older age, Medicare insurance, and higher comorbidity scores were linked to a greater occurrence of AKI, which correlated with increased mortality rates, longer hospital stays, and higher treatment costs.
Article Abstract
Background: Currently, no large, nationwide studies have been conducted to analyze the demographic factors, underlying comorbidities, clinical outcomes, and health care utilization in rhabdomyolysis patients with and without acute kidney injury (AKI).
Methods: We queried the National Inpatient Sample of Healthcare Cost and Utilization Project (HCUP) with patients with rhabdomyolysis from 2016 to 2018. The chi-squared test was used to compare categorical variables, and the adjusted Wald test was employed to compare quantitative variables. The logistic regression model was applied to calculate adjusted odds ratios (ORs) with 95% confidence intervals (95% CIs) to estimate the impact of AKI on outcomes in patients with rhabdomyolysis.
Results: Among 111,085 rhabdomyolysis-related hospitalizations, a higher prevalence of AKI was noticed in older patients (mean age ± SD, 58.2 ± 21.6 vs. 53.8 ± 22.2), Medicare insurance (48.5% vs. 43.2%), and patients with a higher Charlson Comorbidity Index score (CCI 3-5, 15.1% vs. 5.5%). AKI was found to be independently associated with higher mortality (adjusted odds ratio [aOR] 3.33, 95% CI 2.33-4.75), longer hospital stays (adjusted difference 1.17 days, 95% CI: 1.00-1.34), and higher cost of hospital stay (adjusted difference $11,315.05, 95% CI: $9493.02-$13,137.07).
Conclusions: AKI in patients hospitalized with rhabdomyolysis is related to adverse clinical outcomes and significant economic and survival burden.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125267 | PMC |
| http://dx.doi.org/10.3390/jcm10091950 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Kidney Injury Following Cardiac Surgery: A Review of Our Current Understanding.
Am J Cardiovasc Drugs
January 2025
Pediatric Nephrology, State University of Campinas, São Paulo, Brazil.
Around one-quarter of all patients undergoing cardiac procedures, particularly those on cardiopulmonary bypass, develop cardiac surgery-associated acute kidney injury (CSA-AKI). This complication increases the risk of several serious morbidities and of mortality, representing a significant burden for both patients and the healthcare system. Patients with diminished kidney function before surgery, such as those with chronic kidney disease, are at heightened risk of developing CSA-AKI and have poorer outcomes than patients without preexisting kidney injury who develop CSA-AKI.
View Article and Find Full Text PDFHydrogen gas inhalation ameliorates glomerular enlargement after hypoxic-ischemic insult in asphyxiated piglet model.
Sci Rep
January 2025
Department of Pediatrics, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe Mikicho, Kidagun, 761-0793, Kagawa, Japan.
Acute kidney injury (AKI) has been reported to occur in 30-70% of asphyxiated neonates. Hydrogen (H) gas became a major research focus in neonatal medicine after the identification of its robust antioxidative properties. However, the ability of H gas to ameliorate AKI is unknown.
View Article and Find Full Text PDFAcute Kidney and Lung Injuries After Elective Ascending Aortic Surgery.
J Cardiothorac Vasc Anesth
December 2024
Cardiosurgical Intensive Care Unit, Dupuytren II Hospital, University Teaching Hospital of Limoges, Limoges, France; University of Limoges, Tropical Neuroepidemiology, Institute of Epidemiology and Tropical Neurology, GEIST, Limoges, France.
Macrophage membrane-biomimetic ROS-responsive platinum nanozyme clusters for acute kidney injury treatment.
Biomaterials
December 2024
Department of Biotherapy and Department of Hematology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China. Electronic address:
Acute kidney injury (AKI) is a common clinical syndrome characterized by the rapid loss of renal filtration function. No standard therapeutic agent option is currently available. The development and progression of AKI is a continuous and dynamical pathological process.
View Article and Find Full Text PDFBronchiectasis Exacerbation Increases the Risk of Adverse Renal Outcomes-Results From a Large Territory-Wide Cohort Study.
Clin Respir J
January 2025
Division of Nephrology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pok Fu Lam, Hong Kong SAR, China.
Introduction: Bronchiectasis exacerbation (BE) is associated with unfavorable sequelae in other organs such as the cardiovascular system; data regarding its impact on adverse term renal outcomes, however, is lacking.
Methods: A territory-wide retrospective cohort study was conducted in Hong Kong between 1/1/1993 and 31/12/2017. All patients with bronchiectasis followed in the public healthcare system in 2017 were classified as "Exacerbators" or "Non-Exacerbators," and their adverse renal outcomes (renal progression [decrease in eGFR by 30 mL/min lasted for more than 12 months during follow up], acute kidney injury [AKI], and annual rate of eGFR decline) in the ensuing 7 years were compared.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!